September 2016

FDA Approves Amgen’s Amjevita

By: Sandy King  |   September 27, 2016

On Friday, September 23, 2016, the U.S. Food and Drug Administration approved Amgen Inc.’s Amjevita, which is the biosimilar equivalent of AbbVie Inc.’s immunosuppressant Humira. The drug is approved for more than a half-dozen conditions listed on the branded drug’s label, including severe psoriasis and Crohn’s disease.